Cancer Trials Ireland

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

CollaboratorPhase 3Recruiting2023220 people23 Aug 2022clinicaltrials.gov

NCT05123131

Phase 2Active, not recruiting202254 people17 Nov 2021clinicaltrials.gov

NCT04667663

Phase 1Active, not recruiting202116 people16 Dec 2020clinicaltrials.gov

NCT04595565

CollaboratorPhase 3Active, not recruiting20201,332 people20 Oct 2020clinicaltrials.gov

NCT04116047

CollaboratorPhase 3Active, not recruiting2015785 people4 Oct 2019clinicaltrials.gov

NCT03869762

Phase 2Terminated20197 people11 Mar 2019clinicaltrials.gov

NCT03153280

Phase 1Terminated20222 people15 May 2017clinicaltrials.gov

NCT02955810

CollaboratorPhase 1Status unknown201618 people4 Nov 2016clinicaltrials.gov

NCT02950051

CollaboratorPhase 3Completed2016926 people31 Oct 2016clinicaltrials.gov

NCT02582697

CollaboratorPhase 3Recruiting2014500 people21 Oct 2015clinicaltrials.gov

NCT02219178

Phase 2Completed201442 people18 Aug 2014clinicaltrials.gov

NCT01726452

Phase 3Completed2013377 people15 Nov 2012clinicaltrials.gov

NCT01160731

Phase 1Withdrawn20090 people12 Jul 2010clinicaltrials.gov

NCT01158287

Phase 2Completed200954 people8 Jul 2010clinicaltrials.gov

NCT00968643

Phase 3Completed2006126 people31 Aug 2009clinicaltrials.gov

NCT00814541

Phase 2Completed200553 people25 Dec 2008clinicaltrials.gov